Browsing by Subject "SARS"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19
    (Taylor & Francis, 2020-12) Al-Tawfiq, Jaffar A.; Arabi, Yaseen; Medicine, School of Medicine
    The emergence of the COVID-19 pandemic has resulted in a very large number of infections and high number of mortality. There is no specific therapeutic options that are approved for clinical use. Administration of convalescent plasma as a possible therapy was used in the case of viral pneumonia including SARS and influenza. There have been multiple studies of COVID-19 patients utilizing convalescent plasma. These studies employed different dosage levels and different regiments, were observational and lacked control arms, and had variable outcomes. Two of these studies used plasma with anti-SARS-CoV-2 titers of >1:640 to >1:1000. A recent randomized controlled clinical trial showed no benefit of convalescent plasma in patients with severe diseases. However, the study was terminated early and thus further clinical trials are needed to show efficacy in patients with COVID-19 infection.
  • Thumbnail Image
    Item
    Middle East respiratory syndrome coronavirus – The need for global proactive surveillance, sequencing and modeling
    (Elsevier, 2021) Al-Tawfiq, Jaffar A.; Petersen, Eskild; Memish, Ziad A.; Perlman, Stanley; Zumla, Alimuddin; Medicine, School of Medicine
  • Thumbnail Image
    Item
    SARS Another Emerging Disease
    (MAG, 2003-07) Palenik, Charles John; Biomedical and Applied Sciences, School of Dentistry
    Severe acute respiratory syndrome, SARS, is an illness that has been recently reported in Asia, North America, Europe and Africa. SARS appears to be a new disease. The first known case of atypical pneumonia occurred on 16 November 2002 in Foshan City, Guangdong Province, China. However, its significance was not known until later. The disease soon spread to the rest of the Guangdong Province and then further points in South East Asia. The World Health Organization (WHO) started to track the disease actively during mid-February 2003.
  • Thumbnail Image
    Item
    Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy
    (Elsevier, 2013-08-29) Momattin, Hisham; Mohammed, Khurram; Zumla, Alimuddin; Memish, Ziad A.; Al-Tawfiq, Jaffar A.; Department of Medicine, Indiana University School of Medicine
    The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections.